<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000535.v1.p1" parentStudy="phs000535.v1.p1" createDate="2012-08-13" modDate="2012-09-11">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Co-Principal Investigator</td><td>David Solit, MD</td><td>Memorial Sloan-Kettering Cancer Center, New York, NY, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Barry S. Taylor, PhD</td><td>University of California, San Francisco, CA, USA</td></tr>
		<tr><td>Funding Source</td><td>Michael and Zena Wiener for Therapeutic Program in Bladder Cancer</td><td>Memorial Sloan-Kettering Cancer Center, New York, NY, USA</td></tr>
		<tr><td>Funding Source</td><td>Stand Up to Cancer Dream Team Translational Research Grant</td><td>Program of the Entertainment Industry Foundation</td></tr>
		<tr><td>Funding Source</td><td>Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research</td><td>Experimental Therapeutics Center, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genome and Targeted Sequencing of Bladder Cancer</StudyNameEntrez>
	<StudyNameReportPage>Whole Genome and Exon Capture Sequencing of Bladder Cancers</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Cohort</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>One primary bladder cancer and paired peripheral blood sample were subjected to whole genome sequencing on an Illumina HiSeq 2000 platform. This technology was utilized to investigate the genetic basis of a durable remission of metastatic bladder cancer in a patient treated with everolimus, a drug that inhibits the mTOR (mammalian target of rapamycin) signaling pathway. Among the somatic mutations found was a loss-of-function mutation in TSC1 (Tuberous Sclerosis Complex 1), a regulator of mTOR pathway activation. Targeted sequencing using an exon capture and sequencing assay was performed on 13 tumors derived from patients on the same everolimus trial as the index patient and the sequencing data from these tumors is included. TSC1 mutation status was correlated with response to everolimus. The index patient responder tumor and peripheral blood DNA were also subjected to exon capture and sequencing.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>All cases were derived from patients on a phase II study of everolimus performed at Memorial Sloan-Kettering Cancer Center (ClinicalTrials.gov number NCT00805129). Patients were analyzed for which adequate tumor and normal tissue was available for sequencing. DNA was extracted from tumor tissue and from peripheral blood or adjacent normal urothelial tissue.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="12271141"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20164920"/>
		</Publication>
		<Publication>
			<Pubmed pmid="14561707"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17005952"/>
		</Publication>
		<Publication>
			<Pubmed pmid="21047224"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Urinary Bladder Neoplasms"/>
	</Diseases>
	<Attributions>
		<Header title="Co-Principal Investigator">
			<AttName>David Solit, MD</AttName>
			<Institution>Memorial Sloan-Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Barry S. Taylor, PhD</AttName>
			<Institution>University of California, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Michael and Zena Wiener for Therapeutic Program in Bladder Cancer</AttName>
			<Institution>Memorial Sloan-Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Stand Up to Cancer Dream Team Translational Research Grant</AttName>
			<Institution>Program of the Entertainment Industry Foundation</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research</AttName>
			<Institution>Experimental Therapeutics Center, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Geoffrey Beene Cancer Research Center</AttName>
			<Institution>Memorial Sloan-Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000535.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000535.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000535.v1.p1" FileName="eNCI_0143_DUC_8.10.2012.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the standard Data Use Certification. Use of the Data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
